BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Treatment Approaches for Myeloproliferative Neoplasms  

Long-Term Outcomes with Ruxolitinib in Polycythemia Vera

Videos

Expert perspectives on the management of myeloproliferative neoplasms (MPNs) from a virtual tumor board discussion. The segments cover treatment approaches, including the use of JAK inhibitors, and key efficacy and safety data from clinical trials that inform treatment selection.

This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.

Treatment Approaches for Myeloproliferative Neoplasms

Medical experts discuss a patient case highlighting a 68-year old woman who is uninterested in transplantation and treatment with ruxolitinib has been initiated.

Patient Case 1: Patient with Intermediate Risk Myelofibrosis

Expert panelists highlight the COMFORT I and COMFORT II studies.

Review of COMFORT I and COMFORT II Trials

Key findings from COMFORT I and COMFORT II studies are examined.

Expert Takeaways from COMFORT I and II Trial Results

Medical experts discuss strategies to navigate a complex patient scenario pertaining to previous refusal of ASCT.

Managing Treatment Strategy for Patient Who Previously Declined ASCT

Prithviraj Bose, MD, introduces study designs for trials focusing on JAK inhibitor utilization in patients receiving treatment for myelofibrosis.

Key Clinical Trials Highlighting JAK Inhibitors in Myelofibrosis Treatment

The panel of experts dissect findings around breaking JAK inhibitor data in myelofibrosis treatment.

Reviewing Impact of Emerging JAK Inhibitor Data

Dr Bose drives a discussion surrounding the treatment of advanced polycythemia vera.

Treatment of Advanced Polycythemia Vera

Downstream impacts of ruxolitinib in polycythemia vera treatment are illustrated by a panel of medical experts.

This segment discusses the key efficacy and safety considerations from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b as a treatment option for polycythemia vera.

PROUD-PV/CONTINUATION-PV Trials for Ropeginterferon Alfa-2b in Polycythemia Vera

With their final discussion the panel examines the survival outcomes and risk of thromboembolic/hemorrhagic events from the MAJIC-PV trial, which compared ruxolitinib to best available therapy in polycythemia vera patients resistant or intolerant to hydroxyurea.

MAJIC-PV Trial: Ruxolitinib vs Best Available Therapy in Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Expert Perspective Tumor Board

Long-Term Outcomes with Ruxolitinib in Polycythemia Vera

EP: 1.Treatment Approaches for Myeloproliferative Neoplasms

EP: 2.Patient Case 1: Patient with Intermediate Risk Myelofibrosis

EP: 3.Review of COMFORT I and COMFORT II Trials

EP: 4.Expert Takeaways from COMFORT I and II Trial Results

EP: 5.Managing Treatment Strategy for Patient Who Previously Declined ASCT

EP: 6.Key Clinical Trials Highlighting JAK Inhibitors in Myelofibrosis Treatment

EP: 7.Reviewing Impact of Emerging JAK Inhibitor Data

EP: 8.Treatment of Advanced Polycythemia Vera

EP: 9.Long-Term Outcomes with Ruxolitinib in Polycythemia Vera

EP: 10.PROUD-PV/CONTINUATION-PV Trials for Ropeginterferon Alfa-2b in Polycythemia Vera

EP: 11.MAJIC-PV Trial: Ruxolitinib vs Best Available Therapy in Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Newsletter